Showing 8031-8040 of 9119 results for "".
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider
- Dermtech's Noninvasive Melanoma Screen Improves Care, Lowers Costhttps://practicaldermatology.com/news/dermtechs-noninvasive-melanoma-screen-improves-care-lowers-cost/2457700/New research shows that DermTech’s Pigmented Lesion Assay (PLA) reduces cost while improving the care of patients with primary pigmented skin lesions suggestive of melanoma. The
- Life Sciences Industry Eyes $1.5 Trillion Milestonehttps://practicaldermatology.com/news/life-sciences-industry-eyes-15-trillion-milestone/2457703/The life sciences industry is nearing a $1.5 trillion milestone, according to an analysis from Frost & Sullivan. The firm’s Global Life Sciences Industry Outlook, 2018 report finds that healthcare digitization and consumerization, the explosion of patient data, and the emergence of
- Dermatology Authority Adds Credentialing and Licensing Support Serviceshttps://practicaldermatology.com/news/dermatology-authority-adds-credentialing-and-licensing-support-services/2457711/Dermatology Authority has added credentialing and licensing to their list of support services. The requirements for licensing and credentialing differ from city to city, state to state, and procedure to procedure. Dermatology Authority keeps tab
- FDA Approves Braftovi in Combination with Mektovi for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-approves-of-braftovi-in-combination-with-mektovi-for-advanced-braf-mutant-melanoma/2457710/The FDA has approved Array BioPharma Inc.'s BRAFTOVI (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by a
- DermTech Initiating Study to Assess DNA Damage and Reversalhttps://practicaldermatology.com/news/dermtech-initiating-study-to-assess-dna-damage-and-reversal/2457712/DermTech, Inc. has initiated enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potentia
- CBD Naturals to Introduce New Skincare Linehttps://practicaldermatology.com/news/cbd-naturals-to-introduce-new-skincare-line/2457717/Delivering natural beauty from the inside out, CBD Naturals® will introduce Floré™, a prestigious new line of skincare products, at the International Cannabis Business Conference in Vancouver on June 25. Floré™ incorporates cutting-edge ingredient formulas that
- Modern Aesthetics® Set to Launch New Tweet Chat Series-- #RealDealAestheticshttps://practicaldermatology.com/news/modern-aesthetics-set-to-launch-new-tweet-chat-series-realdealaesthetics/2457720/Practical Dermatology’s sister publication, Modern Aesthetics® magazine, is launching a new Tweet chat series --#RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD. The f
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- Valeant: FDA Issues Complete Response Letter for Duobriihttps://practicaldermatology.com/news/valeant-fda-issues-complete-response-letter-for-duobrii/2457723/Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the US FDA